Form 4: Travere Therapeutics CCO Equity Vesting and Tax Sale
Statement of Changes in Beneficial Ownership
Chief Commercial Officer Peter Heerma acquired 4,250 shares via PSU vesting and sold 2,174 shares to cover tax obligations.
Summary
- Peter Heerma, Chief Commercial Officer of Travere Therapeutics, Inc., reported the vesting of performance-based restricted stock units (PSUs).
- On May 4, 2026, 4,250 shares vested following the achievement of cumulative FILSPARI net revenue performance criteria.
- On May 5, 2026, 2,174 shares were sold at $46.65 per share to satisfy mandatory tax withholding obligations.
- Following these transactions, the reporting person holds 140,684 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation and tax compliance, with no signal regarding company performance beyond the previously achieved revenue milestone.
Positives
- Vesting of equity indicates the achievement of specific performance milestones related to FILSPARI net revenue.
- The sale of shares was non-discretionary and strictly for tax withholding purposes.
Negatives
- None identified; the transaction was a standard equity settlement and tax-related sell-to-cover.
Risks
- Future vesting of remaining PSUs is contingent upon continuous service and additional performance criteria.
Future Outlook
The reporting person retains 4,250 unvested PSUs, with an additional 25% of the original grant scheduled to vest on January 31, 2027, subject to continuous service.
Industry Context
StockSavvy.ai notes that this filing reflects standard executive compensation mechanics in the biotechnology sector, where equity incentives are tied to commercial milestones like the net revenue performance of key assets such as FILSPARI.
Comparison to Industry Standards
- The use of performance-based restricted stock units (PSUs) is a standard industry practice for aligning executive compensation with commercial product performance.
- Sell-to-cover transactions for tax obligations are standard practice for corporate officers in the U.S. pharmaceutical industry.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was a non-discretionary tax-related sale.
Next Steps
- Scheduled vesting of additional 25% of PSU grant on January 31, 2027.
Key Dates
| Date | Description |
|---|---|
| 2024-01-31 | Original grant date of performance restricted stock units. |
| 2026-05-04 | Vesting date of 50% of the performance-based restricted stock units. |
| 2026-05-05 | Date of mandatory sell-to-cover transaction for tax obligations. |
| 2027-01-31 | Scheduled vesting date for an additional 25% of the PSU grant. |
Keywords
Travere Therapeutics, TVTX, Form 4, Insider Trading, Equity Compensation, FILSPARI, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.